The receipt of this permission paves way for the marketing of Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) in India
Both companies will promote, market and distribute Sodium Zirconium Cyclosilicate in India under different brand names
Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
Eculizumab is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome
He is an experienced professional in the pharmaceutical industry with about 30 years of progressive experience
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
The company has received five final approvals
The product is expected to be launched in FY25
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
Subscribe To Our Newsletter & Stay Updated
